Moreover, 15% of LCNEC tumors showed genetic changes in P13K/AKT/mTOR pathway; it was also observed that LCNEC might have activating mutations in receptor tyrosine kinase genes such as EGFR, KIT, ERBB2 (Umemura et al., 2014, Miyoshi et al., 2017). This evidence concerns the gene KIT and large cell neuroendocrine carcinoma.